These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 23855668)

  • 21. Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.
    Saha BC; Kumari R; Kushumesh R; Ambasta A; Sinha BP
    Int Ophthalmol; 2022 Jan; 42(1):281-294. PubMed ID: 34453229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma.
    Rao VP; Epstein DL
    BioDrugs; 2007; 21(3):167-77. PubMed ID: 17516712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Progression of drug delivery system for glaucoma].
    Xu Y; Lyu L
    Zhonghua Yan Ke Za Zhi; 2014 Dec; 50(12):946-51. PubMed ID: 25619186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraocular pressure-lowering effects of imidazo[1,2-a]- and pyrimido[1,2-a]benzimidazole compounds in rats with dexamethasone-induced ocular hypertension.
    Marcus AJ; Iezhitsa I; Agarwal R; Vassiliev P; Spasov A; Zhukovskaya O; Anisimova V; Ismail NM
    Eur J Pharmacol; 2019 May; 850():75-87. PubMed ID: 30716317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards axonal regeneration and neuroprotection in glaucoma: Rho kinase inhibitors as promising therapeutics.
    Van de Velde S; De Groef L; Stalmans I; Moons L; Van Hove I
    Prog Neurobiol; 2015 Aug; 131():105-19. PubMed ID: 26093354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
    Abbhi V; Saini L; Mishra S; Sethi G; Kumar AP; Piplani P
    Bioorg Med Chem; 2017 Nov; 25(21):6071-6085. PubMed ID: 29033348
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rho-kinase Inhibitors in Ocular Diseases: A Translational Research Journey.
    Singh K; Singh A
    J Curr Glaucoma Pract; 2023; 17(1):44-48. PubMed ID: 37228304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glaucoma Drugs in the Pipeline.
    Kaufman PL; Mohr ME; Riccomini SP; Rasmussen CA
    Asia Pac J Ophthalmol (Phila); 2018; 7(5):345-351. PubMed ID: 30221499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sustained release ocular drug delivery systems for glaucoma therapy.
    Al-Qaysi ZK; Beadham IG; Schwikkard SL; Bear JC; Al-Kinani AA; Alany RG
    Expert Opin Drug Deliv; 2023; 20(7):905-919. PubMed ID: 37249548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
    Nishio M; Fukunaga T; Sugimoto M; Ikesugi K; Sumi K; Hidaka H; Uji Y
    Curr Eye Res; 2009 Apr; 34(4):282-6. PubMed ID: 19373576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular hypotensive efficacy of Src-family tyrosine kinase inhibitors via different cellular actions from Rock inhibitors.
    Kirihara T; Shimazaki A; Nakamura M; Miyawaki N
    Exp Eye Res; 2014 Feb; 119():97-105. PubMed ID: 24321889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rho-Kinase Inhibitors as Emerging Targets for Glaucoma Therapy.
    Wang J; Wang H; Dang Y
    Ophthalmol Ther; 2023 Dec; 12(6):2943-2957. PubMed ID: 37837578
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of K-115, a rho-kinase inhibitor, on aqueous humor dynamics in rabbits.
    Isobe T; Mizuno K; Kaneko Y; Ohta M; Koide T; Tanabe S
    Curr Eye Res; 2014 Aug; 39(8):813-22. PubMed ID: 24502505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility.
    Honjo M; Tanihara H; Inatani M; Kido N; Sawamura T; Yue BY; Narumiya S; Honda Y
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):137-44. PubMed ID: 11133858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.
    Moura-Coelho N; Tavares Ferreira J; Bruxelas CP; Dutra-Medeiros M; Cunha JP; Pinto Proença R
    Graefes Arch Clin Exp Ophthalmol; 2019 Jun; 257(6):1101-1117. PubMed ID: 30843105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Ocular Hypotensive Efficacy of Topical Fasudil, a Rho-Associated Protein Kinase Inhibitor, in Patients With End-Stage Glaucoma.
    Pakravan M; Beni AN; Ghahari E; Varshochian R; Yazdani S; Esfandiari H; Ahmadieh H
    Am J Ther; 2017; 24(6):e676-e680. PubMed ID: 26825486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma].
    Honjo M
    Nippon Ganka Gakkai Zasshi; 2009 Nov; 113(11):1071-81. PubMed ID: 19994585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia.
    Van de Velde S; Van Bergen T; Sijnave D; Hollanders K; Castermans K; Defert O; Leysen D; Vandewalle E; Moons L; Stalmans I
    Invest Ophthalmol Vis Sci; 2014 Feb; 55(2):1006-16. PubMed ID: 24474276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel drug delivery systems for glaucoma.
    Lavik E; Kuehn MH; Kwon YH
    Eye (Lond); 2011 May; 25(5):578-86. PubMed ID: 21475311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of Rho Kinase Inhibitors on Intraocular Pressure and Aqueous Humor Dynamics in Nonhuman Primates and Rabbits.
    Toris CB; McLaughlin MA; Dworak DP; Fan S; Havens S; Zhan GL; Horan N; Prasanna G
    J Ocul Pharmacol Ther; 2016; 32(6):355-64. PubMed ID: 27266531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.